Cure8 news brief
This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect dosing schedules.
A Phase 2b trial is being launched specifically in Crohn’s disease, so patients and clinicians may see new trial enrollment opportunities and future treatment options if efficacy is confirmed.
Adult patients with moderately-to-severely active Crohn’s disease, clinicians treating IBD, researchers focused on immune pathways or antibody therapeutics, and patients interested in clinical trials or emerging biologic therapies.
Shattuck Labs announced Phase 1 results for SL-325 (a DR3-blocking monoclonal antibody) showing favorable safety, low antidrug-antibody rates, and prolonged blockade of TL1A binding; a randomized double-blind placebo-controlled Phase 2b trial in moderately-to-severely active Crohn’s disease (RECEPTIVE-CD1, ~232 patients, three dose levels) is expected to start Q3 2026 with primary endoscopic response at 12 weeks and data planned in H1 2028.
The company also described a bispecific DR3 x IL-23R candidate (SL-846) in IND-enabling studies with Phase 1 planned in 2027 and preclinical data to be presented at UEG Week.
This is a company press release summarizing early (Phase 1) clinical data and planned trials; Phase 1 is primarily about safety/pharmacology, and Phase 2b will be required to show efficacy. Timelines and expectations are company-provided and subject to change. The announcement includes financial and corporate updates alongside clinical program details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
